Published in Antimicrob Agents Chemother on August 01, 1998
In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother (1999) 1.47
Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob Agents Chemother (2000) 1.30
Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev (2000) 1.26
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob Agents Chemother (2000) 1.20
Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother (2001) 1.19
Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother (2003) 1.14
Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother (2005) 1.02
Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. Antimicrob Agents Chemother (2000) 0.90
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother (2001) 0.86
Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrob Agents Chemother (2000) 0.84
Activities of antimicrobial agents against intracellular pneumococci. Antimicrob Agents Chemother (2000) 0.81
In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae. Antimicrob Agents Chemother (2000) 0.80
Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin. Antimicrob Agents Chemother (2002) 0.80
In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori. Antimicrob Agents Chemother (2001) 0.79
Interaction of the new ketolide ABT-773 (cethromycin) with human polymorphonuclear neutrophils and the phagocytic cell line PLB-985 in vitro. Antimicrob Agents Chemother (2004) 0.78
P-glycoprotein-dependent trafficking of nanoparticle-drug conjugates. Small (2014) 0.77
Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro. Antimicrob Agents Chemother (2001) 0.77
Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. Bioorg Med Chem (2015) 0.75
Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur J Clin Microbiol Infect Dis (2004) 0.75
The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem (1989) 7.13
Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol (1980) 3.14
Photometric determination of lysozyme activity. Proc Soc Exp Biol Med (1955) 2.72
High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother (1987) 2.40
Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob Agents Chemother (1997) 1.52
Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1987) 1.51
Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood (1992) 1.43
Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Antimicrob Agents Chemother (1995) 1.19
Inhibition of neutrophil oxidative metabolism by lysosomotropic weak bases. Blood (1986) 1.19
Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro. J Antimicrob Chemother (1994) 1.15
Mechanism of azithromycin uptake in human polymorphonuclear leucocytes. Arzneimittelforschung (1990) 1.12
Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro. Antimicrob Agents Chemother (1988) 0.99
Inhibition by verapamil of neutrophil responses to formylmethionylleucylphenylalanine and phorbol myristate acetate. Mechanisms involving Ca2+ changes, cyclic AMP and protein kinase C. Biochim Biophys Acta (1985) 0.97
Kinetics of the uptake of antimicrobial agents by human polymorphonuclear leucocytes. Arzneimittelforschung (1989) 0.97
Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res (1995) 0.94
Intracellular bioactivity of macrolides. Clin Microbiol Infect (1996) 0.93
Chromogenic substrates; phenolphthalein glucuronic acid as substrate for the assay of glucuronidase activity. J Biol Chem (1946) 0.93
Effects of dirithromycin and erythromycylamine on human neutrophil degranulation. Antimicrob Agents Chemother (1994) 0.86
Effects of some antimalarial drugs on rat inflammatory polymorphonuclear leukocyte function. Biomed Pharmacother (1989) 0.86
Effect of monodesethyl amodiaquine on human polymorphonuclear neutrophil functions in vitro. Antimicrob Agents Chemother (1991) 0.80
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother (1998) 1.67
[Diffusion of ofloxacin in human lung tissue]. Infection (1986) 1.65
Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob Agents Chemother (1997) 1.52
Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) (1986) 1.52
A new pattern of non-organ- and non-species-specific anti-organelle antibody detected by immunofluorescence: the mitochondrial antibody number 5. Clin Exp Immunol (1978) 1.49
In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother (2000) 1.43
In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Antimicrob Agents Chemother (1996) 1.42
Classification of oral cephalosporins. A matter for debate. Int J Antimicrob Agents (2001) 1.38
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother (1997) 1.30
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother (2003) 1.25
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob Agents Chemother (2000) 1.20
Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Antimicrob Agents Chemother (1995) 1.19
Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother (2000) 1.15
Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro. J Antimicrob Chemother (1994) 1.15
In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob Agents Chemother (2000) 1.13
Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro. Antimicrob Agents Chemother (1986) 1.11
Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany. Microb Drug Resist (2001) 1.08
Viridans group streptococci: a reservoir of resistant bacteria in oral cavities. Clin Microbiol Infect (2002) 1.07
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother (2000) 1.04
Chemokinetic activity of N-formyl-methionyl-leucyl-phenylalanine on human neutrophils, and its modulation by phenylbutazone. Biochem Pharmacol (1982) 1.02
Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison. J Antimicrob Chemother (1985) 1.02
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs. Antimicrob Agents Chemother (1993) 1.01
Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults. Antimicrob Agents Chemother (1984) 0.98
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother (1994) 0.98
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin. J Antimicrob Chemother (1999) 0.98
Redox and activation status of monocytes from human immunodeficiency virus-infected patients: relationship with viral load. J Virol (1999) 0.97
In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 0.97
[RU 28965, a new semi-synthetic macrolide. Bioavailability and pharmacokinetic profile after oral administration]. Pathol Biol (Paris) (1985) 0.97
Diffusion of ofloxacin into human lung tissue. Drugs (1987) 0.95
Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob Agents Chemother (2001) 0.95
Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. Antimicrob Agents Chemother (2000) 0.90
The role of phagocytes in HIV-related oxidative stress. J Clin Virol (2001) 0.90
Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils. Antimicrob Agents Chemother (1999) 0.90
Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2. J Virol (1998) 0.89
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother (2000) 0.89
Cefodizime (HR 221) potentiation of human neutrophil oxygen-independent bactericidal activity. J Antimicrob Chemother (1987) 0.88
Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother (2000) 0.88
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother (1996) 0.88
In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study. J Antimicrob Chemother (1999) 0.87
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother (1995) 0.87
[Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg]. Pathol Biol (Paris) (1986) 0.87
Effects of dirithromycin and erythromycylamine on human neutrophil degranulation. Antimicrob Agents Chemother (1994) 0.86
Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae. Antimicrob Agents Chemother (2002) 0.86
[Macrolides. New therapeutic prospects]. Presse Med (1994) 0.85
The suppository form of antibiotic administration: pharmacokinetics and clinical application. J Antimicrob Chemother (1999) 0.85
[Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin]. Pathol Biol (Paris) (1985) 0.84
Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin. J Antimicrob Chemother (2001) 0.84
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother (1998) 0.83
A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother (1999) 0.82
Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults. Am J Med (1984) 0.81
Effects of cefotaxime and cefodizime on human granulocyte functions in vitro. J Antimicrob Chemother (1986) 0.81
In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens. J Antimicrob Chemother (1998) 0.80
Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin. Antimicrob Agents Chemother (2002) 0.80
Inhibition of human neutrophil protein kinase C activity by the antimalarial drug mefloquine. Biochem Pharmacol (1992) 0.80
The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistance. J Antimicrob Chemother (1999) 0.79
Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. J Antimicrob Chemother (2004) 0.79
Effect of quinine and cinchonine on human neutrophils functions in vitro. J Antimicrob Chemother (1990) 0.79
[HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin]. Pathol Biol (Paris) (1985) 0.79
Interaction of macrolides and ketolides with the phagocytic cell line PLB-985. J Chemother (2003) 0.79
Preparation of stock solutions of macrolide and ketolide compounds for antimicrobial susceptibility tests. Clin Microbiol Infect (2004) 0.79
[Interaction of roxithromycin with human polymorphonuclear neutrophils in vitro and ex vivo]. Pathol Biol (Paris) (1988) 0.79
Production by K 562 cells of an inhibitor of adherence-related functions of human neutrophils. J Immunol (1990) 0.78
Telithromycin--an innovative ketolide antimicrobials. Jpn J Antibiot (2001) 0.78
Antilymphocyte antibodies in progressive systemic sclerosis. Clin Exp Rheumatol (1985) 0.78
Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro. J Antimicrob Chemother (1996) 0.78
The different inhibitory effects of phenylbutazone on soluble and particle stimulation of human neutrophil oxidative burst. Biochem Pharmacol (1983) 0.77
Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey. J Chemother (2005) 0.77
Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro. Antimicrob Agents Chemother (2001) 0.77
Monocyte expression of adhesion molecules in HIV-infected patients: variations according to disease stage and possible pathogenic role. Lab Invest (1999) 0.77
Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. J Antimicrob Chemother (1998) 0.76
Quinine uptake by human polymorphonuclear neutrophils. Antimicrob Agents Chemother (1991) 0.76
[In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes]. Pathol Biol (Paris) (1986) 0.76
In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother (1996) 0.76
[Cefmenoxime concentrations in cerebral ventricles during systemic treatment of Pseudomonas stutzeri ventriculitis]. Presse Med (1985) 0.76
Antibacterial activity of RU44790, a new N-tetrazolyl monocyclic beta-lactam. Antimicrob Agents Chemother (1992) 0.75
Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers. Antimicrob Agents Chemother (1995) 0.75
[Antinuclear, anti-DNA and anti-lymphocyte antibodies in systemic scleroderma. 62 cases]. Rev Rhum Mal Osteoartic (1983) 0.75
Immunomodulating properties of newer cephalosporins: a preliminary classification. Chemioterapia (1987) 0.75
[Pharmacokinetics of cefmenoxime in the aged subject (60 to 90 years of age) after an intravenous injection of 1 g]. Pathol Biol (Paris) (1986) 0.75
[Cefmenoxime diffusion into cerebrospinal fluid during human purulent meningitis]. Pathol Biol (Paris) (1985) 0.75
Anti-pseudomonal activity of HR 810. Infection (1985) 0.75
Ofloxacin: antibacterial activity, induction of resistance and killing curves. Chemioterapia (1985) 0.75
[In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime]. Pathol Biol (Paris) (1985) 0.75
Behaviour of cefmenoxime towards beta-lactamases. Drugs Exp Clin Res (1985) 0.75
[In vitro antibacterial activity of cefpirome in combination with 4 aminoglycosides and 2 fluoroquinolones]. Pathol Biol (Paris) (1988) 0.75
[Clinical evaluation of cefmenoxime in urinary tract and prostatic infections]. Pathol Biol (Paris) (1985) 0.75
[Therapeutic prospects of new fluoroquinolones]. Presse Med (1985) 0.75
In vitro evaluation of faropenem activity against anaerobic bacteria. J Chemother (2005) 0.75
[Polymyositis and subcutaneous fat necrosis, manifestations of toxoplasmosis origin]. Presse Med (1989) 0.75
[In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime]. Pathol Biol (Paris) (1986) 0.75
[Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins]. Pathol Biol (Paris) (1985) 0.75
Study of the diffusion of cefmenoxime into the bronchial secretions. Chemotherapy (1986) 0.75
[Cefpirome (HR 810). A new broad spectrum cephalosporin]. Pathol Biol (Paris) (1985) 0.75
Interaction of cefotaxime versus desacetyl cefotaxime on human neutrophil functions. Chemioterapia (1987) 0.75
Penetration of cefmenoxime into cerebrospinal fluid of patients with bacterial meningitis. J Antimicrob Chemother (1986) 0.75
[Diffculties in medico-social management of tuberculosis in Pneumology Departement of Fann University Teaching Hospital]. Dakar Med (2004) 0.75
[Role of Clostridium and its toxin in pseudo-membranous colitis (author's transl)]. Ann Biol Clin (Paris) (1981) 0.75